CClinicalTrials.gg
RecruitingNCT04727398Updated Oct 10, 2023

The Incidence of Complete Posterior Vitreous Degeneration After Phacoemulsification

An interventional study of Wide-field optical coherence tomography (Optovue®) in Posterior Vitreous Detachment, sponsored by Khon Kaen University. Recruiting at 1 site in Thailand. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Khon Kaen University · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Study summary

Intraocular surgery could induce vitreous degeneration and then abnormal posterior vitreous detachment (PVD) could occur including vitreoschisis and partial-thickness PVD. Vitreomacular interface (VMI) abnormalities such as epimacular membrane were observed following many intraocular surgeries. The incidence of peripheral break and epimacular membrane (EMM) after pneumatic retinopexy were 11.7% and 4-11%, respectively. Although multiple intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections induced PVD of 5.6%, but peripheral break was reported as only 0.67%. The incidence of rhegmatogenous retinal detachment (RRD) after phacoemulsification is gradually increased with time. The accumulative risk of RRD was increased from 0.27% at 1 year to 1.27% at 20 years after phacoemulsification.

Read the detailed description

The most common intraocular surgery is cataract surgery. From the literature review, many methods were used to detect the PVD after phacoemulsification. The former studies used indirect ophthalmoscopy and ocular ultrasound for diagnosis of PVD. The later studies used the optical coherence tomography (OCT) for PVD detection. The OCT device had higher effectiveness in evaluation of the posterior segment, and then it can detect post-phacoemulsification PVD more and early than previous studies. Ivastinovic et al demonstrated 59.2% of patients had PVD at 1 month after phacoemulsification, and increased up to 71.4% at 3 months.

Tsukahara et al introduced wide-field OCT-based PVD classification. The advance OCT device will be useful in detection of abnormal PVD and it's sequelae. If the risk factors of post-phacoemulsification PVD were explored, the prevention of abnormal PVD and VMI disorders could be done.

02

Conditions studied

  • Posterior Vitreous Detachment

Browse trials for

Keywords

  • posterior vitreous detachment
  • phacoemulsification
03

In context

Vitreous Detachment

22 studies on the registry are indexed under Vitreous Detachment; 4 are open to participants now.

This study's planned enrollment of 92 is above the median of 43 across 14 interventional studies indexed under Vitreous Detachment.

Browse Vitreous Detachment studies →

Lead sponsor

Khon Kaen University is the lead sponsor of 160 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Cataract patients who was scheduled for phacoemulsification
  • Age >50 years
  • No complete PVD was detected by OCT
  • Can be taken the wide-field OCT images
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Secondary cataract)
  • History of ocular trauma or head trauma
  • Systemic diseases that can cause the intraocular problems such as connective tissue disease
  • History of other ocular diseases such as glaucoma, uveitis and vitreoretinal disorders
  • History of intraocular laser treatment
  • History of intraocular surgery such as intravitreal drug injection

Withdrawal Criteria:

  • Intraoperative complications such as posterior capsular rupture and zonule dialysis
  • Postoperative complications such as vitreous hemorrhage and postoperative endophthalmitis
  • Undergo the intraocular surgery during the follow-up period
  • Receiving the intraocular laser treatment during the follow-up period such as laser capsulotomy and panretinal photocoagulation
  • Having the ocular trauma or head trauma during the follow-up period
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Other
    Cataract patients who was scheduled for phacoemulsification

    Wide-field optical coherence tomography was performed before the surgery, and then was done at 1, 3, 6 and 12 months following the phacoemulsification.

    Device: Wide-field optical coherence tomography (Optovue®)

Interventions

  • DeviceWide-field optical coherence tomography (Optovue®)

    Merged 4 images for wide-filed OCT-based PVD classification, 2 vertical line images and 2 horizontal line images

06

What researchers measure

Primary outcomes

  1. The incidence of PVD after phacoemulsification

    incidence of complete PVD

    Time frame: 12 months

Secondary outcomes

  1. The incidence of VMI disorders

    e.g. Epimacular membrane, Vitreomacular traction, Peripheral retinal break

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Khon Kaen University
    Khon Kaen, 40002, Thailand
    • Suthasinee Sinawat, MD · Contact · ssuthasinee@kku.ac.th · +66 815454594
    • Kwanchanok Chanthowong, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04727398
Lead sponsor
Khon Kaen University
Responsible party
Suthasinee Sinawat (Associate Professor, Khon Kaen University) — Principal investigator
First posted
Jan 27, 2021
Start date
Sep 3, 2021
Primary completion
Dec 30, 2024 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Oct 10, 2023

Study contacts

Suthasinee Sinawat, MD
Contact
ssuthasinee@kku.ac.th
+66 81 5454594
Suthasinee Sinawat, MD
principal investigator · KKU Eye Center, Department of Ophthalmology, Faculty of Medicine, Khon Kaen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion